person · Reporting owner

Foley Mark J

Disclosed activity across 4 companies

Tapewire entity: 35933
SEC CIK: 0001529196

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GLAUKOS CorpGKOS · Entity 3510	Director	May 28, 2026	June 23, 2026
SI-BONE, Inc.SIBN · Entity 2501	Director	June 16, 2020	June 18, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GLAUKOS Corp

Report date May 28, 2026 · Filed June 23, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.52 · Expires 2036-05-28	Direct	2,987	Reported balance After 2026-05-28 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-05-28 · Grant · Acquired 2,987 · Balance 2,987 F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above. F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4A amends a Form 4 filed June 1, 2026 that incorrectly reported the exercise price of options granted to the Reporting Person on May 28, 2026 as $53.57. The correct exercise price for the options granted is $106.52, as shown above.

F2: Granted pursuant to the Issuer's Director Compensation Policy. Vests in full on the one-year anniversary of grant date.

SI-BONE, Inc.

Report date June 16, 2020 · Filed June 18, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,797	Reported balance After 2020-06-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-06-16 · Grant · Acquired 8,797 · Balance 8,797 F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.

F2: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Revance Therapeutics, Inc.

Report date February 04, 2025 · Filed February 06, 2025

Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2025-02-06 transaction · row 5 4 source rows · reconciled sequence Row 1 · 2025-02-04 · Other · Disposed 996,935 · Balance 27,933 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 3 · 2025-02-06 · Disposition to issuer · Disposed 27,933 · Balance 0 F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Row 4 · 2025-02-06 · Grant · Acquired 84,686 · Balance 84,686 F4: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement. Row 5 · 2025-02-06 · Disposition to issuer · Disposed 84,686 · Balance 0 F5: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement).
Common StockSEC Table I · non-derivative	IndirectSee footnote	0	Reported balance After 2025-02-04 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-02-04 · Other · Disposed 110,913 · Balance 0 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. F2: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.

F2: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002.

F3: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).

F4: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement.

F5: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement).

Zeltiq Aesthetics Inc

Report date April 28, 2017 · Filed April 28, 2017

Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-28 transaction · row 1 1 source row Row 1 · 2017-04-28 · Disposition to issuer · Disposed 173,787 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2022-08-23	Direct	Reported balance After 2017-04-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-04-28 · Disposition to issuer · Disposed 572,435 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.04 · Expires 2022-08-23	Direct	Reported balance After 2017-04-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-28 · Disposition to issuer · Disposed 758,667 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.06 · Expires 2022-06-14	Direct	Reported balance After 2017-04-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-04-28 · Disposition to issuer · Disposed 9,536 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2022-04-27	Direct	Reported balance After 2017-04-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-04-28 · Disposition to issuer · Disposed 121,236 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2024-02-24	Direct	Reported balance After 2017-04-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-04-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.65 · Expires 2025-02-18	Direct	Reported balance After 2017-04-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-04-28 · Disposition to issuer · Disposed 26,277 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2026-02-27	Direct	Reported balance After 2017-04-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-04-28 · Disposition to issuer · Disposed 124,610 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.89 · Expires 2027-01-17	Direct	Reported balance After 2017-04-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-04-28 · Disposition to issuer · Disposed 72,254 · Balance 0 F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.

F2: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 03, 2022 Filed Jan 6, 2022 01:55 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantCommon Stock	2,486	$0.00	$0.00	Disclosure SEC source: 0001104659-22-001661 · tm221974-1_4seq1.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,238 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 4,868 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document
November 29, 2021 Filed Nov 29, 2021 21:24 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	PurchaseCommon Stock	40,000	$12.90	$515,924.00	Disclosure SEC source: 0001479290-21-000169 · wf-form4_163823903263601.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 110,913 F1 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.76 to $13.0305. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. Read SEC document
October 13, 2021 Filed Oct 15, 2021 20:00 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	Tax withholdingCommon Stock	42,096	$23.08	$971,575.68	Disclosure SEC source: 0001479290-21-000158 · wf-form4_163434239998355.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,065 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2021, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock awards ("RSA's") for 400,000 shares. The RSA's vest in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document
June 30, 2021 Filed Jul 2, 2021 19:52 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	OtherCommon Stock	882	$24.09	$21,246.50	Disclosure SEC source: 0001479290-21-000130 · wf-form4_162526991461391.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811,161 F1 · kind: These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2021 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
June 03, 2021 Filed Jun 7, 2021 23:04 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantCommon Stock	2,382	$0.00	$0.00	Disclosure SEC source: 0001104659-21-077837 · tm2119039-5_4seq.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,752 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,566 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document
February 02, 2021 Filed Feb 4, 2021 21:10 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantEmployee Stock Option (Right to Buy) · Derivative	73,665	$0.00 Strike: $28.01	$0.00	Disclosure SEC source: 0001479290-21-000028 · wf-form4_161249099366159.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,665 Underlying: Common Stock · 73,665 shares Expires 2031-02-01 F3 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2021, subject to Mr. Foley's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document
February 02, 2021 Filed Feb 4, 2021 21:10 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	40,715	$0.00	$0.00	Disclosure SEC source: 0001479290-21-000028 · wf-form4_161249099366159.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,279 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document
January 04, 2021 Filed Jan 7, 2021 02:30 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantCommon Stock	1,184	$0.00	$0.00	Disclosure SEC source: 0001104659-21-001753 · a4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,370 F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 5,084 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document
October 13, 2020 Filed Oct 15, 2020 18:57 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	Tax withholdingCommon Stock	66,106	$27.62	$1,825,847.72	Disclosure SEC source: 0001628280-20-014509 · wf-form4_160280262897368.xml · nonDerivative · entry 3 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 769,564 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on October 13, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 133,332 shares. The RSA vests in three equal annual installments from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document
September 30, 2020 Filed Oct 2, 2020 20:33 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	Tax withholdingCommon Stock	143,269	$25.14	$3,601,782.66	Disclosure SEC source: 0001628280-20-014244 · wf-form4_160168522471281.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,231 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on September 30, 2020, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA. Read SEC document
September 30, 2020 Filed Oct 2, 2020 20:33 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	301,000	$0.00	$0.00	Disclosure SEC source: 0001628280-20-014244 · wf-form4_160168522471281.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,500 F1 · shares: Represents shares of Common Stock received upon partial settlement of a performance share award (the "PSA") on September 30, 2020. Read SEC document
July 23, 2020 Filed Oct 15, 2020 18:57 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	50,913	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-014509 · wf-form4_160280262897368.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 70,913 F1 · price: On July 23, 2020. the Issuer completed acquisition (the "Merger") of Hint, Inc. ("HintMD") pursuant to that certain Agreement and Plan of Merger, dated as of May 18, 2020, by and among the Issuer, HeartMerger Sub, Inc., direct wholly-owned subsidiary of the Issuer, HintMD, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by Mr. Foley and the Foley Family Trust in HintMD were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. F2 · ownership.nature: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. Read SEC document
July 23, 2020 Filed Oct 15, 2020 18:57 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	264,439	Not disclosed	Not disclosed	Disclosure SEC source: 0001628280-20-014509 · wf-form4_160280262897368.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,670 F1 · price: On July 23, 2020. the Issuer completed acquisition (the "Merger") of Hint, Inc. ("HintMD") pursuant to that certain Agreement and Plan of Merger, dated as of May 18, 2020, by and among the Issuer, HeartMerger Sub, Inc., direct wholly-owned subsidiary of the Issuer, HintMD, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by Mr. Foley and the Foley Family Trust in HintMD were automatically cancelled and converted into the right to receive shares of common stock of the Issuer. Read SEC document
June 16, 2020 Filed Jun 18, 2020 23:10 UTC	SI-BONE, Inc. SIBN · Entity 2501	GrantCommon Stock	8,797	$0.00	$0.00	Disclosure SEC source: 0001562180-20-004591 · primarydocument.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 03, 2020 Filed Jun 6, 2020 01:51 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantCommon Stock	3,900	$0.00	$0.00	Disclosure SEC source: 0001127602-20-019061 · form4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,186 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 3,900 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document
January 23, 2020 Filed Jan 24, 2020 20:22 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	200,000	$0.00	$0.00	Disclosure SEC source: 0001479290-20-000021 · wf-form4_157991534708581.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,500 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document
October 13, 2019 Filed Oct 15, 2019 20:23 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantEmployee Stock Option (Right to Buy) · Derivative	740,000	$0.00 Strike: $12.18	$0.00	Disclosure SEC source: 0001479290-19-000103 · wf-form4_157118535567459.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 740,000 Underlying: Common Stock · 740,000 shares Expires 2029-10-12 F3 · derivative.exercise_price: The fair market value was determined on October 11,2019 pursuant to the Plan. F4 · derivative.exercise_date: The Option vests in accordance to the following schedule: 25% of the shares subject to the Option shall vest on the first anniversary of the vesting commencement date of October 13, 2019, and 1/48th of the shares vesting each month thereafter for the remaining three years, subject to Mr. Foley's Continuous Service (as defined in the Plan) as of each such vesting date. Read SEC document
October 13, 2019 Filed Oct 15, 2019 20:23 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	200,000	$0.00	$0.00	Disclosure SEC source: 0001479290-19-000103 · wf-form4_157118535567459.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,500 F1 · shares: The shares subject to the Restricted Stock award shall vest in three (3) equal annual installments beginning from October 13, 2019, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date. Read SEC document
June 13, 2019 Filed Jun 17, 2019 23:41 UTC	SI-BONE, Inc. SIBN · Entity 2501	GrantStock Options (Right to buy) · Derivative	26,236	$0.00 Strike: $17.72	$0.00	Disclosure SEC source: 0001562180-19-003577 · primarydocument.xml · derivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,236 Underlying: Common Stock · 26,236 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares subject to the option will vest in a series of 36 equal monthly increments over three years starting on the Vesting Commencement Date, such that the shares subject to the option will be fully vested on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Issuer's Board of Directors on each applicable vesting date. Read SEC document
May 30, 2019 Filed Jun 1, 2019 00:06 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantCommon Stock	2,653	$0.00	$0.00	Disclosure SEC source: 0001104659-19-033243 · a4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,286 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Includes 2,653 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document
May 09, 2019 Filed May 10, 2019 20:52 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	9,000	$0.00 Strike: $12.82	$0.00	Disclosure SEC source: 0001479290-19-000054 · wf-form4_155753595933818.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 9,000 shares Expires 2029-05-08 F3 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 9, 2020, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 09, 2019 Filed May 10, 2019 20:52 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001479290-19-000054 · wf-form4_155753595933818.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 9, 2020, subject to Mr. Foley's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
May 31, 2018 Filed Jun 1, 2018 20:35 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantCommon Stock	4,633	$0.00	$0.00	Disclosure SEC source: 0001562180-18-002763 · primarydocument.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,633 F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock. F2 · balance_after: Consists of 4,633 restricted stock units that have not yet vested or been delivered to the Reporting Person. Read SEC document
May 10, 2018 Filed May 11, 2018 20:26 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to buy) · Derivative	6,000	$0.00 Strike: $29.15	$0.00	Disclosure SEC source: 0001479290-18-000077 · wf-form4_152608473930197.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-05-09 F3 · derivative.exercise_date: The shares subject to the stock option shall vest on the one year anniversary, May 10, 2019, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. Read SEC document
May 10, 2018 Filed May 11, 2018 20:26 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001479290-18-000077 · wf-form4_152608473930197.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 10, 2019, subject to Mr. Foley's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. Read SEC document
December 13, 2017 Filed Dec 14, 2017 23:39 UTC	GLAUKOS Corp GKOS · Entity 3510	GrantStock option (right to buy) · Derivative	15,000	$0.00 Strike: $25.77	$0.00	Disclosure SEC source: 0001562180-17-003880 · primarydocument.xml · derivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-13 F1 · derivative.exercise_date: Granted pursuant to the Issuer's 2015 Omnibus Incentive Compensation Plan. Vests in full on May 31, 2018. Read SEC document
November 07, 2017 Filed Nov 9, 2017 19:47 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	PurchaseCommon Stock	500	$27.45	$13,725.00	Disclosure SEC source: 0001209191-17-060104 · doc4.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 20,000 F2 · ownership.nature: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. Read SEC document
November 07, 2017 Filed Nov 9, 2017 19:47 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	PurchaseCommon Stock	19,500	$26.95	$525,443.10	Disclosure SEC source: 0001209191-17-060104 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 19,500 F1 · price: The price reported in Table I, Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.425 to $27.425. Mr. Foley undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · ownership.nature: These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:44 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $24.55	$0.00	Disclosure SEC source: 0001179110-17-012138 · edgar.xml · derivative · entry 2 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-09-04 F2 · derivative.exercise_date: The shares subject to the stock option shall vest on September 5, 2018, the one year anniversary of the grant date, subject to Mr. Foley's Continuous Service (as defined in the Plan) through such vesting date. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:44 UTC	Revance Therapeutics, Inc. RVNC · Entity 83521	GrantCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0001179110-17-012138 · edgar.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents a restricted stock award (the "RSA"). The shares underlying the RSA shall vest on September 5, 2018, the one year anniversary of the grant date, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan") through such vesting date. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	72,254	$0.00 Strike: $40.89	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 9 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,254 shares Expires 2027-01-17 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	124,610	$0.00 Strike: $23.03	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 8 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,610 shares Expires 2026-02-27 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	26,277	$0.00 Strike: $34.65	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 7 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,277 shares Expires 2025-02-18 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $21.00	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 6 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2024-02-24 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	121,236	$0.00 Strike: $6.38	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 5 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121,236 shares Expires 2022-04-27 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	9,536	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 4 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,536 shares Expires 2022-06-14 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	758,667	$0.00 Strike: $5.04	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 3 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 758,667 shares Expires 2022-08-23 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerStock Option (Right to Buy) · Derivative	572,435	$0.00 Strike: $5.04	$0.00	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · derivative · entry 2 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 572,435 shares Expires 2022-08-23 F2 · derivative.exercise_date: In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all shares subject to this option were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 28, 2017 Filed Apr 28, 2017 13:28 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Disposition to issuerCommon Stock	173,787	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-028606 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc. a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer (the "Board"), whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). In connection with the Merger, the Board accelerated and vested in full all equity awards held by the Reporting Person as of immediately prior to the closing of the Merger. Pursuant to the terms of the Merger Agreement, all 173,787 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes. Read SEC document
April 07, 2017 Filed Apr 12, 2017 11:27 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	GiftCommon Stock	37,667	$0.00	$0.00	Disclosure SEC source: 0001209191-17-026639 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,787 Read SEC document
March 13, 2017 Filed Mar 14, 2017 10:59 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	GiftCommon Stock	8,976	$0.00	$0.00	Disclosure SEC source: 0001209191-17-020383 · doc4.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,454 Read SEC document
March 13, 2017 Filed Mar 14, 2017 10:59 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	SaleCommon Stock	10,000	$55.77	$557,659.00	Disclosure SEC source: 0001209191-17-020383 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,430 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.735 to $55.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 24, 2017 Filed Feb 27, 2017 18:02 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Tax withholdingCommon Stock	4,565	$55.62	$253,905.30	Disclosure SEC source: 0001209191-17-014926 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,430 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 24, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on February 24, 2014 for 35,000 shares. The RSUs vested with respect to 25% of the underlying shares on February 24, 2015 and the remaining shares shall vest annually at a rate of 25% per year, subject to the Reporting Person's continued service to the Issuer. Read SEC document
February 19, 2017 Filed Feb 22, 2017 15:36 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Tax withholdingCommon Stock	7,843	$55.67	$436,619.81	Disclosure SEC source: 0001209191-17-013120 · doc4.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,995 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 19, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted on February 29, 2016 for 65,421 shares. The RSUs vest annually at a rate of 25% per year beginning from February 19, 2016, subject to the Reporting Person's continued service to the Issuer. Read SEC document
February 19, 2017 Filed Feb 22, 2017 15:36 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	Tax withholdingCommon Stock	4,962	$55.67	$276,234.54	Disclosure SEC source: 0001209191-17-013120 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,838 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 19, 2017, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on February 19, 2015 for 52,554 shares. The RSUs vest as follows: 25% of the total number of shares subject to the restricted stock units vested on February 19, 2016, and the remainder vest annually at a rate of 25% per year, subject to the Reporting Person's continued service to the Issuer. Read SEC document
February 13, 2017 Filed Feb 15, 2017 13:34 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	SaleCommon Stock	10,000	$55.69	$556,871.00	Disclosure SEC source: 0001209191-17-010985 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.5550 to $55.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
January 18, 2017 Filed Jan 20, 2017 19:06 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	GrantStock Option (right to buy) · Derivative	72,254	$0.00 Strike: $40.89	$0.00	Disclosure SEC source: 0001209191-17-004984 · doc4.xml · derivative · entry 2 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,254 Underlying: Common Stock · 72,254 shares Expires 2027-01-17 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option vest on January 18, 2018, and the remainder vest in equal monthly installments over a 36-month period thereafter, subject to the Reporting Person's continued service to the Issuer. Read SEC document
January 18, 2017 Filed Jan 20, 2017 19:06 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	GrantCommon Stock	37,861	$0.00	$0.00	Disclosure SEC source: 0001209191-17-004984 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,800 F1 · security: Represents grant of restricted stock units payable solely in common stock that vest in four equal annual installments, with the vesting commencement date of January 18, 2017. Read SEC document
January 13, 2017 Filed Jan 17, 2017 11:10 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	SaleCommon Stock	10,000	$41.72	$417,170.00	Disclosure SEC source: 0001209191-17-003817 · doc4.xml · nonDerivative · entry 1 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,939 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $41.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
December 14, 2016 Filed Dec 15, 2016 11:20 UTC	Zeltiq Aesthetics Inc ZLTQ · Entity 176636	GiftCommon Stock	22,500	$0.00	$0.00	Disclosure SEC source: 0001209191-16-155302 · doc4.xml · nonDerivative · entry 2 Foley Mark J · CIK 0001529196 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,939 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.